Date Source Title Access 1 5 May 2019 Hitanshu Dhingra, Adelaide Equity & Partners Ltd A deep dive into Paradigm's OA program and partnering prospects Download PDF 2 23 Jan 2019 Marc Sinatra, Lodge Partners Paradigm Biopharmaceuticals: Mucoplysaccharidosis and what’s to come going forward: BUY Download PDF 3 Nov 25 2018 Fiftyone Capital The Next Australian Blockbuster Biotech Access link 4 5 June 2018 Fiftyone Capital Paradigm Biopharmaceuticals Ltd Research Access link
research reports and media, page-2
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $87.44M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.0¢ | 24.5¢ | $76.64K | 309.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 50386 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.5¢ | 11539 | 3 |
View Market Depth
| Last trade - 13.39pm 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
25.0¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 25.0¢ | 25.0¢ | 24.5¢ | 19823 | ||
| Last updated 13.34pm 05/06/2024 ? | |||||
| PAR (ASX) Chart |